Hepatic action of vasopressin: Lack of a role for adenosine-3′,5′-cyclic monophosphate  by Kirk, C.J. & Hems, D.A.
Volume 47. number 1 FEBS LETTERS October 1974 
HEPATIC ACTION OF VASOPRESSIN: 
LACK OF A ROLE FOR ADENOSINE-3’S’-CYCLIC MONOPHOSPHATE 
C. J. KIRK and D. A. HEMS 
Department of Biochemistry, Imperial College of Science and Technology London, S. W. 7, UK 
Received 7 August 1974 
1. Introduction 
Vasopressin (anti-diuretic hormone) can stimulate 
glycogen breakdown and gluconeogenesis in the rat 
liver, at concentrations (0. I - 1 .O ng/ml) which can occur 
in the intact rat [l] . This is a third major systemic 
action of vasopressin in rats; its concentration- 
dependence [I] resembles that of the pressor action, 
rather than the anti-diuretic effect. The hepatic action 
of vasopressin therefore has significance in the intact 
animal, in conditions where plasma vasopressin levels 
are high, such as haemorrhagic shock [2] , and warrants 
further investigation. 
The question arises of the mechanism of the hepatic 
action of vasopressin. A simple theory would be that 
adenosine cyclic-3’,5’-monophosphate (cyclic AMP) is 
implicated. To investigate this possibility, concentra- 
tions of cyclic - AMP have been measured in the liver 
of intact rats, and in the medium during perfusion, in 
conditions where glucogon and adrenalin produced a 
rise in concentration of this nucleotide [3-51. 
In this report, it is shown that vasopressin does not 
produce an increase in cyclic AMP in the liver or 
perfusate, in any of the conditions tested. Thus the 
hepatic effect of vasopressin provides a clearcut 
example of a short-term hormonal effect on mammalian 
metabolic processes, which is not mediated by cyclic 
AMP. 
2. Materials and methods 
2.1. Perfusion of rat liver 
Livers of fed rats (170-190 g) were perfused with 
50 ml recirculating bicarbonate buffered medium con- 
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taining albumin and washed rat erythrocytes [I]. After 
40 min, during which a steady perfusate glucose concen- 
tration was established, hormones were added to the 
perfusate, to give the following initial concentrations; 
glucagon, 10 r&ml; adrenalin, 1 Oe6 M; vasopressin, 
100 mU/mlitre. Over the next 30 min, samples of the 
dripping effluent medium were collected for analysis 
of cyclic AMP. Glucose was measured in samples taken 
from the reservoir of perfusion medium. Adrenalin and 
vasopressin produced transient decreases in flow rate. 
2.2. Experiments with intact rats 
Rats were anaesthetised with Nembutal. The 
abdomen was opened, to permit injection of hormones 
(in 0.25 ml 0.9% Na Cl) into the hepatic portal vein; 
glucagon, 1 .O pg; adrenalin 1.5 X lo-’ mol; vasopressin 
10 or 100 mu. Control injections were 0.9% Na C 1. 
After various times, the liver was removed for 
measurement of cyclic AMP. During this period, the 
abdomen was covered with tissue moistened with 0.9% 
Na Cl, and the rat kept warm by a nearby bulb. Only 
one sample was taken from each rat. In preliminary 
experiments, it was established that steady basal 
(lowest) hepatic cyclic AMP concentrations were 
attained 15-20 min after opening the abdomen. At 
earlier times, the concentration was about 50% higher. 
Therefore a delay of 20 min after opening the abdomen 
was routinely employed before hormone injection. 
2.3. Analytical methods 
Cyclic AMP was measured by a radioisotope satura- 
tion assay [6]. Samples of liver were quick-frozen in 
liquid Nz, and extracted in 10 vols (w/v) of 6% (w/v) 
TCA (trichloroacetic acid); 200-400 1.11 of extract was 
washed 4 times with water-saturated iethyl ether to 
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remove the TCA, dried and taken up in buffer contain- 
ing theophylline and mercapto-ethanol for assay [6]. 
Perfusion medium was spun to remove erthrocytes, 
and mixed with an equal volume of buffer, heated at 
100°C for 3 min and centrifuged to remove protein. 
Standard samples (0.5-5 pmol), taken through the 
same procedure, gave reproducible standard curves 
(range of counts bound 50-90% of that in the absence 
of cyclic AMP); Recovery of added cyclic AMP from 
liver extracts was 95-115%; Separate experiments 
showed that vasopressin did not affect the extraction 
or binding of cyclic AMP. Glucose was measured by a 
glucose oxidase method. 
2.4. Chemicals 
Ladrenalin bitartrate and [&arginine] vasopressin 
were from Sigma Chemical Co., and glucagcn was 
kindly donated by Eli-Lilly Ltd. (courtesy of Dr. M. 
Root). Cyclic AMP was from C. F. Boehringer Corp. 
Ltd., or Radiochemical Centre, Amersham, UK 
(3 H-labelled). Other materials for perfusion and 
analysis were of the highest grade commercially 
available. 
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Fig. 1. Effect of hormones on hepatic cyclic AMP in vivo. Fed 
rats were anaesthetized; the hepatic content of cyclic AMP 
was determined at various times after the injection, into the 
hepatic portal vein, of: glucagon, 1 pg (4); adrenalin, 1.5 X 
1OW8 mol (m); vasopressin (10 mu, 0; 100 mu, 0); or 0.9% 
(w/v) NaCl (A). Other details are in the text. Results are means 
of 3-6 measurements; bars indicate S.E.M. 
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Fig. 2. Effect of hormones on venous effluent cyclic AMP in 
the perfused liver. Livers of fed rats were perfused with re- 
circulating bicarbonate buffered saline, and cyclic AMP was 
measured in the dripping effluent medium; hormones were 
added, after 40 min, to the following initial concentrations: 
glucagon, 10 ng/ml (A); adrenalin, low6 M (9); vasopressin, 
100 mu/ml (0). No additions: (A). Other details are in the text. 
Results are means from 3 perfusions; bars indicate S.E.M. 
3. Results 
3.1. Experiments in vivo 
In intact rats, intravenous glucagon and adrenalin 
produced the expected rise in the hepatic concentra- 
tion of cyclic AMP (fig. 1). These effects were of the 
same order as those previously reported [3-51. 
Vasopressin (10 mU or 100 mu) produced no detectable 
increase in hepatic cyclic AMP (fig. 1). 
3.1. Experiments with the perfused liver 
In the perfused liver, as in vivo, glucagon and 
adrenalin caused an increase in the concentration 
of cyclic AMP in the effluent (fig. 2: see refs. [3-5,7]). 
Again, vasopressin did not bring about an increase in 
the perfusate cyclic AMP (fig. 2), despite causing 
glucose output which was of the same order as that 
previously observed [l] , and that produced by 
adrenalin (fig. 3). 
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Fig. 3. Effect of hormones on hepatic glucose output. Livers 
were perfused as described in fig. 2. Glucose was measured in 
the main reservoir of medium being initially about 5 mM. The 
extra glucose released uring perfusion was calculated. Other 
details are as described in fig. 2. 
4. Discussion 
Present results confirm the action of vasopressin in 
stimulating glucose output in the rat liver [I] . Several 
considerations suggested that this effect might be 
mediated by cyclic AMP. Thus the hepatic action of 
glucagon (for which the minimally effective dose is 
also about 0.1 ng/mI) and the renal action of vasopressin, 
appear to involve cyclic AMP ([3-5,8] respectively). 
More generally, it appears that most hormones which 
exert clearcut rapid effects on metabolic processes can 
influence the concentration of cyclic AMP in the target 
tissue [9] . 
The lack of an effect of vasopressin on hepatic cyclic 
AMP concentrations, observed in the present experi- 
ments, is in agreement with the lack of effect of 
vasopressin on hepatic adenyl cyclase (reported in ref. 
[ 151 and confirmed: separate personal communications 
from Rodbell and Hanoune). 
In summary, the glycogenolytic action of vasopressin 
on the liver appears to be unique among short-term 
‘catabolic’ hormone effects in mammals (reported so 
far) in being associated with no discernible alteration 
in tissue cyclic AMP concentration. 
However, in the present study, no increase in cyclic 
AMP were detected in liver or perfusate, in response to 
vasopressin concentrations that were maximal or 
supramaximal in regard to their effect on glucose output 
[ 11. This negative result was not a consequence of any 
limitation in the conditions of the experiments, or in 
the determination of cyclic AMP, since glucagon and 
adrenalin produced the expected increases in cyclic 
AMP. 
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